Comparing a new injection to standard treatment for diabetic macular edema
Treatments studied
Part of Eyes & vision clinical trials.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have swelling in the center of your retina (macula) from diabetes, even if you've never been treated for it before.
- Your vision in the eye being studied must be between 20/200 and 20/32 on an eye chart.
- If you've had eye injections before, your last one must have been at least 12 weeks ago and you must have had at least one in the past year.
- The vision in your other eye (the one not being studied) must be 20/250 or better.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This study tests whether a new drug (AVT29) is as safe and effective as the standard treatment Eylea HD for people with diabetic macular edema (DME) — a condition where fluid builds up in the back of the eye due to diabetes. If you have vision loss from DME and haven't had anti-VEGF injections before, you may be able to join.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.